A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it sho...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2020-11, Vol.11 (47), p.4457-4462
Main Authors: de Velasco, Guillermo, Carril-Ajuria, Lucia, Guerrero-Ramos, Felix, Alonso-Gordoa, Teresa, Rodríguez-Moreno, Juan F, Carretero, Alberto, Martin-Soberon, Maricruz, de la Rosa-Kehrmann, Federico, Castellano, Daniel
Format: Article
Language:English
Subjects:
Case Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373
cites cdi_FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373
container_end_page 4462
container_issue 47
container_start_page 4457
container_title Oncotarget
container_volume 11
creator de Velasco, Guillermo
Carril-Ajuria, Lucia
Guerrero-Ramos, Felix
Alonso-Gordoa, Teresa
Rodríguez-Moreno, Juan F
Carretero, Alberto
Martin-Soberon, Maricruz
de la Rosa-Kehrmann, Federico
Castellano, Daniel
description Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment. This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.
doi_str_mv 10.18632/oncotarget.27807
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7720770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33315988</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373</originalsourceid><addsrcrecordid>eNpVUdtKJDEQDYvLKq4f4IvkB0Zzme6kX4Rx8AYDLos-N-mkYkd6kibJjIx_458aR3dW66GqoM45VcVB6JiSUyprzs6C1yGr-Aj5lAlJxA90QJtpM2FVxfe-9PvoKKUnUqKaCsmaX2ifc06rRsoD9DrDWiXACaKDhIPFyqyV12BwBK8GrGEoSUXtfFgqPKrswOeEcwSVC-rZ5R57CMo8rQoxF2wXXkrjvOvwGF2IOAesNzlEMCud3RoKfuwj6ByWm62A8zj3gMf-_RSG57OLuz9_L8sOp4bf6KdVQ4Kjz3qIHq4u7-c3k8Xd9e18tphoJqmYiAaspUJ0FKDiRHBS8bqqG2gEk8Z2goAxpNLTTmglp6aWrLZdbaWkxAIX_BCdf-iOq24JRpcvoxra8sFSxU0blGu_T7zr28ewboVgRAhSBOiHgI4hpQh2x6Wk3VrW_res3VpWOCdfl-4Y_wzibxyTmfU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial</title><source>PubMed Central</source><creator>de Velasco, Guillermo ; Carril-Ajuria, Lucia ; Guerrero-Ramos, Felix ; Alonso-Gordoa, Teresa ; Rodríguez-Moreno, Juan F ; Carretero, Alberto ; Martin-Soberon, Maricruz ; de la Rosa-Kehrmann, Federico ; Castellano, Daniel</creator><creatorcontrib>de Velasco, Guillermo ; Carril-Ajuria, Lucia ; Guerrero-Ramos, Felix ; Alonso-Gordoa, Teresa ; Rodríguez-Moreno, Juan F ; Carretero, Alberto ; Martin-Soberon, Maricruz ; de la Rosa-Kehrmann, Federico ; Castellano, Daniel</creatorcontrib><description>Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment. This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.27807</identifier><identifier>PMID: 33315988</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Case Report</subject><ispartof>Oncotarget, 2020-11, Vol.11 (47), p.4457-4462</ispartof><rights>Copyright: © 2020 de Velasco et al.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373</citedby><cites>FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720770/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720770/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33315988$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>de Velasco, Guillermo</creatorcontrib><creatorcontrib>Carril-Ajuria, Lucia</creatorcontrib><creatorcontrib>Guerrero-Ramos, Felix</creatorcontrib><creatorcontrib>Alonso-Gordoa, Teresa</creatorcontrib><creatorcontrib>Rodríguez-Moreno, Juan F</creatorcontrib><creatorcontrib>Carretero, Alberto</creatorcontrib><creatorcontrib>Martin-Soberon, Maricruz</creatorcontrib><creatorcontrib>de la Rosa-Kehrmann, Federico</creatorcontrib><creatorcontrib>Castellano, Daniel</creatorcontrib><title>A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment. This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.</description><subject>Case Report</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUdtKJDEQDYvLKq4f4IvkB0Zzme6kX4Rx8AYDLos-N-mkYkd6kibJjIx_458aR3dW66GqoM45VcVB6JiSUyprzs6C1yGr-Aj5lAlJxA90QJtpM2FVxfe-9PvoKKUnUqKaCsmaX2ifc06rRsoD9DrDWiXACaKDhIPFyqyV12BwBK8GrGEoSUXtfFgqPKrswOeEcwSVC-rZ5R57CMo8rQoxF2wXXkrjvOvwGF2IOAesNzlEMCud3RoKfuwj6ByWm62A8zj3gMf-_RSG57OLuz9_L8sOp4bf6KdVQ4Kjz3qIHq4u7-c3k8Xd9e18tphoJqmYiAaspUJ0FKDiRHBS8bqqG2gEk8Z2goAxpNLTTmglp6aWrLZdbaWkxAIX_BCdf-iOq24JRpcvoxra8sFSxU0blGu_T7zr28ewboVgRAhSBOiHgI4hpQh2x6Wk3VrW_res3VpWOCdfl-4Y_wzibxyTmfU</recordid><startdate>20201124</startdate><enddate>20201124</enddate><creator>de Velasco, Guillermo</creator><creator>Carril-Ajuria, Lucia</creator><creator>Guerrero-Ramos, Felix</creator><creator>Alonso-Gordoa, Teresa</creator><creator>Rodríguez-Moreno, Juan F</creator><creator>Carretero, Alberto</creator><creator>Martin-Soberon, Maricruz</creator><creator>de la Rosa-Kehrmann, Federico</creator><creator>Castellano, Daniel</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20201124</creationdate><title>A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial</title><author>de Velasco, Guillermo ; Carril-Ajuria, Lucia ; Guerrero-Ramos, Felix ; Alonso-Gordoa, Teresa ; Rodríguez-Moreno, Juan F ; Carretero, Alberto ; Martin-Soberon, Maricruz ; de la Rosa-Kehrmann, Federico ; Castellano, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Case Report</topic><toplevel>online_resources</toplevel><creatorcontrib>de Velasco, Guillermo</creatorcontrib><creatorcontrib>Carril-Ajuria, Lucia</creatorcontrib><creatorcontrib>Guerrero-Ramos, Felix</creatorcontrib><creatorcontrib>Alonso-Gordoa, Teresa</creatorcontrib><creatorcontrib>Rodríguez-Moreno, Juan F</creatorcontrib><creatorcontrib>Carretero, Alberto</creatorcontrib><creatorcontrib>Martin-Soberon, Maricruz</creatorcontrib><creatorcontrib>de la Rosa-Kehrmann, Federico</creatorcontrib><creatorcontrib>Castellano, Daniel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>de Velasco, Guillermo</au><au>Carril-Ajuria, Lucia</au><au>Guerrero-Ramos, Felix</au><au>Alonso-Gordoa, Teresa</au><au>Rodríguez-Moreno, Juan F</au><au>Carretero, Alberto</au><au>Martin-Soberon, Maricruz</au><au>de la Rosa-Kehrmann, Federico</au><au>Castellano, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2020-11-24</date><risdate>2020</risdate><volume>11</volume><issue>47</issue><spage>4457</spage><epage>4462</epage><pages>4457-4462</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Cytoreductive nephrectomy has long been used to improve disease control in metastastic Renal Cell Carcinoma (mRCC). However, based on the results of the CARMENA and SURTIME trials, cytoreductive nephrectomy is no longer the standard of care in patients requiring upfront systemic treatment and it should be avoided in most poor-risk patients. Nevertheless, it should still be considered in patients responding to systemic therapy and good-risk patients not requiring systemic treatment. This case series of the phase 2 CABOPRE trial suggests neoadjuvant cabozantinib may be able to induce rapid and significant responses in some intermediate-risk advanced renal cell carcinoma patients facilitating resectability.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>33315988</pmid><doi>10.18632/oncotarget.27807</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2020-11, Vol.11 (47), p.4457-4462
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7720770
source PubMed Central
subjects Case Report
title A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A09%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20series%20of%20advanced%20renal%20cell%20carcinoma%20patients%20treated%20with%20neoadjuvant%20cabozantinib%20prior%20to%20cytoreductive%20nephrectomy%20within%20the%20phase%202%20CABOPRE%20trial&rft.jtitle=Oncotarget&rft.au=de%20Velasco,%20Guillermo&rft.date=2020-11-24&rft.volume=11&rft.issue=47&rft.spage=4457&rft.epage=4462&rft.pages=4457-4462&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.27807&rft_dat=%3Cpubmed_cross%3E33315988%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2817-79eff177b1ee530730536569e9728dfb70edd05c4b7ca84d6826fb6f8810fe373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33315988&rfr_iscdi=true